• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

    5/29/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date.

    Roth Capital Partners acted as sole placement agent for the offering.

    The gross proceeds to the Company from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.

    The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-287423), as amended, that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on May 28, 2025. The offering was made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained at the SEC's website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at [email protected].

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About Revelation Biosciences, Inc.

    Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

    For more information on Revelation, please visit www.RevBiosciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250529330792/en/

    Company Contacts

    Mike Porter

    Investor Relations

    Porter LeVay & Rose Inc.

    Email: [email protected]

    Chester Zygmont, III

    Chief Financial Officer

    Revelation Biosciences Inc.

    Email: [email protected]

    Get the next $REVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years

      5/29/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial

      5/29/25 8:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

      5/23/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chawla Lakhmir S was granted 181 shares (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:14:40 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carver Jennifer was granted 181 shares, increasing direct ownership by 3,017% to 187 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:12:17 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roper Jess was granted 181 shares, increasing direct ownership by 9,050% to 183 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:09:20 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Revelation Biosciences with a new price target

      Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

      2/17/22 8:17:25 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

      5/8/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

      3/6/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

      11/8/24 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Revelation Biosciences Inc.

      PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      5/29/25 4:09:16 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Revelation Biosciences Inc.

      424B3 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      5/29/25 9:44:19 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Revelation Biosciences Inc.

      EFFECT - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      5/29/25 12:15:19 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

      5/23/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

      – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

      1/13/25 6:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

      Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

      10/2/23 9:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

      SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/13/24 8:12:05 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      1/3/24 8:36:37 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/21/23 4:49:56 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care